Jakob Loven
QuietNamed in filings at JuviaOn the current fund
- Board seats filed
- 6
all filings on record
Named in filings at JuviaOn the current fund
all filings on record
last 24 months
from a verified or cited source
| Hexagon Bio | Biotech & pharma | June 2021 | Nextech Invest, The Column Group |
| IconOVir Bio | Biotech & pharma | December 2020 | Nextech Invest, Vida Ventures |
| A2 Biotherapeutics | Biotech & pharma | September 2020 | Nextech Invest, The Column Group, Vida Ventures |
| Vividion Therapeutics | Biotech & pharma | April 2019 | ARCH Venture Partners, Nextech Invest, Versant Venture Capital |
| Arrakis Therapeutics | Biotech & pharma | April 2019 | Nextech Invest, Venbio Global Strategic |
| ARVINAS | Biotech & pharma | March 2018 | Nextech Invest |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The category is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Categories of companies where filings name Jakob Loven on the board, based on 6 filed seats with a verified or cited source.